ASIA unversity:Item 310904400/111561
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 90570/105786 (86%)
造訪人次 : 16376349      線上人數 : 337
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋


    請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/111561


    題名: Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study.
    作者: Lin, Shih-Yi;Lin, Shih-Yi;Lin, Cheng-Li;Lin, Cheng-Li;Che, Hsien-Te;Chen, Hsien-Te;高嘉鴻;Kao, Chia-Hung;*
    貢獻者: 生物資訊與醫學工程學系
    關鍵詞: Thyroid cancer, levothyroxine, osteoporosis, cohort study
    日期: 2018-05
    上傳時間: 2018-10-22 11:28:09 (UTC+8)
    摘要: Background: The outcomes of thyroid cancer patients using levothyroxine are largely undetermined.

    Methods: The study population consisted of 9398 patients newly diagnosed with thyroid cancer; their data was retrieved from a subset of the National Health Insurance Research Database of Taiwan during the period of 1999–2011. In this nationwide retrospective cohort study, we compared the risk of osteoporosis among thyroid cancer patients with levothyroxine use, those without levothyroxine use, and propensity-score-matched non-thyroid controls. We also investigated the duration–response and dose–response relationships between levothyroxine use and the risk of osteoporosis. The competing risk was also analyzed.

    Results: The mean duration of follow-up was 6.63 years for patients without thyroid cancer, 5.45 years for thyroid cancer patients without levothyroxine use, and 6.46 years for thyroid cancer patients with levothyroxine use. The incidence of osteoporosis was higher in the thyroid cancer cohort than in the non-thyroid-cancer cohort (8.69 vs. 6.60 per 1000 person-years, respectively), with an adjusted hazard ratio of 1.39 (95% confidence interval [CI] = 1.22–1.58). Thyroid cancer patients with levothyroxine use exhibited a significantly higher risk of osteoporosis than non-thyroid-cancer patients, while thyroid cancer patients not using levothyroxine did not have significant higher risks than non-thyroid-cancer patients. Compared with patients without thyroid cancer, the risk of osteoporosis increased from 1.53 (95% CI = 0.91–2.57) in patients receiving a cumulative dose of ≤265 mg levothyroxine, to 3.62 in those receiving a cumulative dose of >395 mg levothyroxine (95% CI = 2.16–6.06).

    Conclusion: Our population-based cohort study showed that thyroid cancer patients receiving levothyroxine have a higher risk of osteoporosis.
    關聯: CURRENT MEDICAL RESEARCH AND OPINION
    顯示於類別:[生物資訊與醫學工程學系 ] 期刊論文

    文件中的檔案:

    檔案 大小格式瀏覽次數
    index.html0KbHTML188檢視/開啟


    在ASIAIR中所有的資料項目都受到原著作權保護.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋